Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Thor Medical ASAFRA:8NN -3.85%27 Debt-to-Equity is 0.59 as of Jun. 2026, which is 2850% above its 10-year median of 0.02. GuruFocus rates FRA:8NN with a GF Score™ of 27/100. The stock has 3 warning signs investors should review. Among 963 Biotechnology companies, Thor Medical ASA ranks worse than 79.02% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Thor Medical ASA's Debt-to-Equity or its related term are showing as below:
FRA:8NN'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.02 Max: 0.59
Current: 0.59
During the past 13 years, the highest Debt-to-Equity Ratio of Thor Medical ASA was 0.59. The lowest was 0.00. And the median was 0.02.
FRA:8NN's Debt-to-Equity is ranked worse than 79.02% of 963
companies
in the Biotechnology industry
Industry Median: 0.16
vs FRA:8NN: 0.59
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Thor Medical ASA Debt-to-Equity Related Terms
Thor Medical ASA Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Thor Medical ASA's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8NN vs VRTX, REGN, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Thor Medical ASA's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thor Medical ASA Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Thor Medical ASA's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Thor Medical ASA's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thor Medical ASA (FRA:8NN) has a Debt-to-Equity of 0.59 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Thor Medical ASA and its competitors. This is 2850% above median its historical median of 0.02. According to the industry distribution chart, Thor Medical ASA ranks #761 out of 963 companies in the Biotechnology industry, placing it in the top 79%.
Is Thor Medical ASA's Debt-to-Equity too high?
Thor Medical ASA's current Debt-to-Equity of 0.59 is 2850% above median its 10-year median of 0.02. The Biotechnology industry median Debt-to-Equity is 0.16. Thor Medical ASA's value of 0.59 is 268.8% above this industry median. Based on the distribution chart, Thor Medical ASA ranks #761 out of 963 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Thor Medical ASA has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Thor Medical ASA's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Thor Medical ASA ranks #761 out of 963 companies for Debt-to-Equity. This places Thor Medical ASA in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Thor Medical ASA's value of 0.59 is 268.8% above this benchmark. While the company's 10-year median is 0.02 vs. the industry median of 0.16, Thor Medical ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thor Medical ASA's current Debt-to-Equity of 0.59 is 268.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Thor Medical ASA and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thor Medical ASA's current Debt-to-Equity is 0.59, which is 2850% above median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thor Medical ASA stock overvalued right now?
Thor Medical ASA (FRA:8NN) has a current Debt-to-Equity of 0.59. The current Debt-to-Equity is 0.59, which is 2850% above median its 10-year median of 0.02 and 268.8% above the Biotechnology industry median of 0.16. Thor Medical ASA's overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Thor Medical ASA (FRA:8NN), the current Debt-to-Equity is 0.59 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Thor Medical ASA is a Norway-based biopharmaceutical company. The company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. It uses a proprietary production process that does not involve irradiation or nuclear reactors to produce alpha-emitting materials. These materials are used by radiopharmaceutical companies in the development of cancer therapies.
27GF Score
Get the complete analysis for FRA:8NN
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8NN has been successfully added to your 
